Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Summary

The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit). The main questions to answer are: * The safety and tolerability of AON-D21 vs placebo. * The efficacy of AON-D21vs placebo. * The pharmacokinetics of AON-D21. * The pharmacodynamics of AON D21. * To identify biomarkers for patient stratification and analyses in future trials.

Timeline

Start

2024-02-02

Primary completion

2026-03-16

Completion

2026-03-16

Drugs

Indications